Oligodendroglial tumor
MONDO:0018744Oligodendrogliomas are cerebral tumors that are differentiated from other gliomas on the basis of their unique genetic characteristics and better response to chemotherapy. These tumors are classified according to their grade (low grade oligodendrogliomas: grade II of the WHO classification and anaplastic oligodendrogliomas: grade III of the WHO classification) and according to their pure or mixed histology (oligoastrocytomas).
Also known as: oligodendroglial neoplasm, oligodendroglial tumor
2881 clinical trials for this condition and its sub-types, 2 tagged with Oligodendroglial tumor itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Oligodendroglial tumor
-
Oligodendroglioma 62 trials
4 sub-types
- Adult oligodendroglioma 3 trials
- Childhood oligodendroglioma 1 trial
- Brain oligodendroglioma 0 trials Sub-types →
- Spinal cord oligodendroglioma 0 trials
-
Anaplastic oligodendroglioma 22 trials · 37 incl. sub-types
1 sub-type
- IDH-mutant and 1p/19q-codeleted oligodendroglioma 10 trials · 15 incl. sub-types Sub-types →
Most studied deeper sub-types
-
Could waiting on radiation save your brain? new trial investigates
Disease control Recruiting nowThis study is for people with a specific type of slow-growing brain tumor (oligodendroglioma) that needs treatment beyond surgery. The goal is to see if waiting to start radiation until the tumor grows back can help protect memory and thinking skills, without shortening how long …
Phase 3 • Sponsor: Hospices Civils de Lyon • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New drug tarlatamab targets Hard-to-Treat brain tumors
Disease control Recruiting nowThis phase 2 trial tests tarlatamab, a drug that helps immune cells attack tumor cells, in 44 adults with recurrent IDH-mutant gliomas (a type of brain tumor). The study aims to see if tarlatamab can increase immune cell activity in the tumor and potentially control the disease. …
Phase 2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 26, 2026 19:02 UTC